close 73% inwestorów detalicznych traci pieniądze podczas handlu CFD z tym dostawcą. Inwestowanie wiąże się z ryzykiem i nie jest odpowiednie dla wszystkich inwestorów. Kontrakty CFD są złożonymi instrumentami i wiążą się z dużym ryzykiem szybkiej utraty środków pieniężnych z powodu dźwigni finansowej. 73% rachunków inwestorów detalicznych notuje stratę pieniędzy podczas handlu kontraktami CFD z tym dostawcą. Upewnij się, czy rozumiesz, jak działają kontrakty CFD, i czy możesz pozwolić sobie na wysokie ryzyko utraty pieniędzy.
Change languagePolski
Pulpit

LLY

1,078.2

+0.12%↑

JNJ

207.38

-0.05%↓

ABBV

230.82

+0.29%↑

UNH

328.79

-0.84%↓

AZN

92.49

-0.43%↓

LLY

1,078.2

+0.12%↑

JNJ

207.38

-0.05%↓

ABBV

230.82

+0.29%↑

UNH

328.79

-0.84%↓

AZN

92.49

-0.43%↓

LLY

1,078.2

+0.12%↑

JNJ

207.38

-0.05%↓

ABBV

230.82

+0.29%↑

UNH

328.79

-0.84%↓

AZN

92.49

-0.43%↓

LLY

1,078.2

+0.12%↑

JNJ

207.38

-0.05%↓

ABBV

230.82

+0.29%↑

UNH

328.79

-0.84%↓

AZN

92.49

-0.43%↓

LLY

1,078.2

+0.12%↑

JNJ

207.38

-0.05%↓

ABBV

230.82

+0.29%↑

UNH

328.79

-0.84%↓

AZN

92.49

-0.43%↓

Strona główna・Stock List・Karyopharm Therapeutics Inc
Search

Karyopharm Therapeutics Inc

Closed

SectorHealthcare

7.23 -2.17

Strong Buy

Price update 29 gru 2025, 20:59 UTC

BuySell

Overview

Share price change

24h

Current

Min

7.06

Max

7.4

Key metrics

By Trading Economics

Income

4.1M

-33M

Sales

6.1M

44M

EPS

-3.82

Profit margin

-75.213

Employees

279

EBITDA

1.8M

-23M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+85.89% upside

Market Stats

By TradingEconomics

Market Cap

22M

124M

Previous open

9.4

Previous close

7.23

News Sentiment

By Acuity

50%

50%

149 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

5.9501 / 7.66 Support & Resistance

Karyopharm Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

29 gru 2025, 22:03 UTC

Major Market Movers

Mining Stocks Slip Near the End of Stellar Year

DJ

Read

29 gru 2025, 15:57 UTC

Major Market Movers

Praxis Shares Rise on Ulixacaltamide Breakthrough Designation

DJ

Read

29 gru 2025, 23:43 UTC

Market Talk

Nikkei May Decline; Yen in Focus -- Market Talk

DJ

Read

29 gru 2025, 23:38 UTC

Acquisitions, Mergers, Takeovers

Manus: Will Continue to Operate From Singapore

DJ

Read

29 gru 2025, 23:38 UTC

Acquisitions, Mergers, Takeovers

Manus: Will Continue to Sell, Operate Product Subscription Service Through App, Website

DJ

Read

29 gru 2025, 23:37 UTC

Acquisitions, Mergers, Takeovers

Meta Platforms: Will Integrate Manus Service Into Products

DJ

Read

29 gru 2025, 23:36 UTC

Acquisitions, Mergers, Takeovers

Meta Platforms: Will Continue to Operate, Sell Manus Service

DJ

Read

29 gru 2025, 23:36 UTC

Acquisitions, Mergers, Takeovers

Meta Platforms: Manus's Talent to Join Team to Deliver General-Purpose Agents Across Consumer, Business Products

DJ

Read

29 gru 2025, 23:35 UTC

Acquisitions, Mergers, Takeovers

Manus to Join Meta Platforms

DJ

Read

29 gru 2025, 21:33 UTC

Acquisitions, Mergers, Takeovers

Origin: Raise Values Kraken at US$8.65 Billion

DJ

Read

29 gru 2025, 21:33 UTC

Acquisitions, Mergers, Takeovers

Origin: Octopus Targeting Kraken Separation by Mid 2026

DJ

Read

29 gru 2025, 21:31 UTC

Acquisitions, Mergers, Takeovers

BlueScope: Rezoning Will Allow for Range of Commercial, Industrial Development Uses

DJ

Read

29 gru 2025, 21:31 UTC

Acquisitions, Mergers, Takeovers

BlueScope Also Says Land Adjacent to Port Kembla Steelworks Rezoned to Special Purpose

DJ

Read

29 gru 2025, 21:30 UTC

Acquisitions, Mergers, Takeovers

Origin's Kraken Stake to Remain at 22.7%

DJ

Read

29 gru 2025, 21:30 UTC

Acquisitions, Mergers, Takeovers

Origin Will Continue to Hold Its 22.7% Interest in Octopus

DJ

Read

29 gru 2025, 21:30 UTC

Acquisitions, Mergers, Takeovers

BlueScope: Guidance Reflects Sustained Strength of Operating Performance in Recent Months

DJ

Read

29 gru 2025, 21:30 UTC

Acquisitions, Mergers, Takeovers

Origin: Additional Interest Offsets Dilution From Raise

DJ

Read

29 gru 2025, 21:30 UTC

Acquisitions, Mergers, Takeovers

BlueScope Doesn't Expect Material Impact on 1H Guidance Range

DJ

Read

29 gru 2025, 21:29 UTC

Acquisitions, Mergers, Takeovers

Origin Waiving Australia Exclusivity to Kraken in Exchange for Additional 1.5% Equity Interest

DJ

Read

29 gru 2025, 21:29 UTC

Acquisitions, Mergers, Takeovers

BlueScope Expects to Complete Property Sale for A$76 Million Consideration

DJ

Read

29 gru 2025, 21:29 UTC

Acquisitions, Mergers, Takeovers

BlueScope Expects to Complete Property Sale in 2H of FY 2026

DJ

Read

29 gru 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

BlueScope: Selling Residentially Zoned Land in West Dapto to Large Homebuilder

DJ

Read

29 gru 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

Origin: Kraken's Raise Paves Way for Separation From Octopus Energy

DJ

Read

29 gru 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

Origin: Kraken to Raise Total US$1 Billion From New, Existing Investors

DJ

Read

29 gru 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

BlueScope Steel Exchanges Contracts for Sale of 33 Hectares of Land in West Dapto

DJ

Read

29 gru 2025, 21:27 UTC

Acquisitions, Mergers, Takeovers

Origin Energy to Invest US$140M in Kraken's Standalone Equity Raise

DJ

Read

29 gru 2025, 20:22 UTC

Market Talk

Oil Rebounds As Russia-Ukraine War Seen Continuing -- Market Talk

DJ

Read

29 gru 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Futures Rise As Front Month Expires -- Market Talk

DJ

Read

29 gru 2025, 20:02 UTC

Acquisitions, Mergers, Takeovers

Union Pacific--Norfolk Southern Merger Targets Trucking Market Share -- Barrons.com

DJ

Read

29 gru 2025, 17:36 UTC

Market Talk

U.S. Natural Gas Inventories Swing to Deficit Vs. 5-Year Average -- Market Talk

DJ

Read

Peer Comparison

Price change

Karyopharm Therapeutics Inc Forecast

Price Target

By TipRanks

85.89% upside

12 Months Forecast

Average 13.83 USD  85.89%

High 21 USD

Low 6 USD

Based on 6 Wall Street analysts offering 12 month price targets forKaryopharm Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

5

Buy

1

Hold

0

Sell

Based on 6 analysts giving stock ratings to Karyopharm Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

5.9501 / 7.66Support & Resistance

Short Term

Bullish Evidence

Recent bullish events outweigh bearish events.

Intermediate Term

Strong Bearish Evidence

All events are bearish.

Long Term

No Evidence

There are no events.

Sentiment

By Acuity

149 / 374 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

Other stocks from the sector

LLY

Eli Lilly and Co.

1,078.2

↑ +0.12%

JNJ

Johnson and Johnson

207.38

↓-0.05%

ABBV

AbbVie Inc

230.82

↑ +0.29%

UNH

UnitedHealth Group Inc

328.79

↓-0.84%

AZN

AstraZeneca PLC ADR

92.49

↓-0.43%
help-icon Live chat